The tumor microenvironment modulation market is poised for growth driven by increasing focus on advanced immunotherapies, tumor biology understanding, and combination cancer treatments. Expansion is ...

Optical interconnects, leveraging intrinsic advantages such as high bandwidth, low loss, and immunity to electromagnetic interference (EMI), are thus regarded as a promising solution to these barriers ...

The development of the 6G standard is entering a more concrete phase. At the June 2026 3GPP RAN Plenary in Singapore, the industry advanced several key areas under study and finalized the timeline for ...

A new approach for identifying signs of hidden awareness in people who cannot speak or move after severe brain injury has ...

Bupropion conferred modest reductions in cancer-related fatigue compared with placebo, according to results of a randomized ...

Immune checkpoint blockade (ICB) has reshaped the treatment landscape for advanced hepatocellular carcinoma (HCC), offering ...

It's built like a tank and sounds the bomb ...

Sionna Therapeutics targets cystic fibrosis with novel CFTR/NBD1 stabilization; key 2026 readouts and cash runway to 2028.

Recent advances in single-cell sequencing and spatial multi-omics have transformed our ability to resolve tumor ecosystems at unprecedented resolution.

Akari Therapeutics, Plc (Nasdaq: AKTX), an oncology biotechnology company developing antibody drug conjugates (ADCs) with novel RNA splicing modulator payloads, today announced the completion of its ...

On June 15, 2026, Circular Action Alliance (CAA) submitted its inaugural Program Plan to California’s Packaging Producer Responsibility ...

Data from ongoing Phase 1 study of AX-0810 in healthy volunteers demonstrated dose-dependent target engagement on all key biomarkers in the ...